These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19433555)

  • 41. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
    Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
    Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 44. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.
    Nagler M; Gregor M; Wuillemin WA
    Acta Haematol; 2011; 126(2):119-21. PubMed ID: 21659727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
    Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD
    Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
    Kennedy GA; Morris KL; Subramonpillai E; Curley C; Butler J; Durrant S
    Br J Haematol; 2013 Jun; 161(6):794-801. PubMed ID: 23590671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deferasirox induced liver injury in haemochromatosis.
    Aslam N; Mettu P; Marsano-Obando LS; Martin A
    J Coll Physicians Surg Pak; 2010 Aug; 20(8):551-3. PubMed ID: 20688025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
    Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deferasirox (Exjade): a new iron chelator.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
    [No Abstract]   [Full Text] [Related]  

  • 52. Deferasirox.
    Stumpf JL
    Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
    Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
    Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
    Ruffo GB; Borsellino Z; Cuccia L; Marocco MR; Gagliardotto F; Tarantino R
    Clin Drug Investig; 2010; 30(4):267-73. PubMed ID: 20225910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N; Finelli C; Porta MD; Fenaux P; Ganser A; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Domokos G; Roubert B; Rose C;
    Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.